Prediction of lncRNA and disease associations based on residual graph convolutional networks with attention mechanism DOI Creative Commons
Sheng‐Chang Wang, Jiaqing Qiao,

Shou Feng

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 2, 2024

LncRNAs are non-coding RNAs with a length of more than 200 nucleotides. More and evidence shows that lncRNAs inextricably linked diseases. To make up for the shortcomings traditional methods, researchers began to collect relevant biological data in database used bioinformatics prediction tools predict associations between diseases, which greatly improved efficiency study. improve accuracy current we propose new lncRNA-disease method attention mechanism, called ResGCN-A. Firstly, integrated lncRNA functional similarity, Gaussian interaction profile kernel disease semantic similarity obtain comprehensive similarity. Secondly, residual graph convolutional network was extract local features Thirdly, mechanism assign weight above further potential Finally, training set required by Extra-Trees classifier obtained concatenating features, diseases were trained classifier. ResGCN-A combines realize global fusion is beneficial accurate accuracy. In experiment, compared five other methods through 5-fold cross-validation. The results show AUC value AUPR 0.9916 0.9951, superior methods. addition, case studies robustness evaluation have shown an effective predicting associations. source code will be available at https://github.com/Wangxiuxiun/ResGCN-A .

Language: Английский

EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions DOI Open Access
Mehrdad Hashemi, Hamid Zaferani Arani,

Sima Orouei

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 155, P. 113774 - 113774

Published: Oct. 3, 2022

One of the malignant tumors in women that has involved both developed and developing countries is breast cancer. Similar to other types tumors, cancer cells demonstrate high metastatic nature. Besides, tumor have ability drug resistance. EMT related mechanism metastasis focus current manuscript highlighting function malignancy Breast increase their migration by induction During EMT, N-cadherin vimentin levels increase, E-cadherin decrease mediate EMT-induced invasion. Different kinds anti-cancer agents such as tamoxifen, cisplatin paclitaxel mediates chemoresistance feature cells. Furthermore, correlates with radio-resistance tumor. Clinical aspect reversing preventing chemotherapy or radiotherapy failure patients improving survival time. The anti-tumor suppress can be used for decreasing invasion increasing chemosensitivity lncRNAs, miRNAs factors modulate progression are discussed here.

Language: Английский

Citations

99
Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions DOI Open Access
Mehrdad Hashemi,

Sara Etemad,

Sahar Rezaei

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 158, P. 114204 - 114204

Published: Jan. 4, 2023

Glioblastoma (GBM) is one of the most malignant cancers central nervous system and due to its sensitive location, surgical resection has high risk therefore, chemotherapy radiotherapy are utilized for treatment. However, chemoresistance radio-resistance other problems in GBM Hence, new therapies based on genes recommended treatment GBM. PTEN a tumor-suppressor operator cancer that inhibits PI3K/Akt/mTOR axis diminishing growth, metastasis drug resistance. In current review, function PTEN/PI3K/Akt progression evaluated. Mutation or depletion leads increase progression. Low expression level mediates poor prognosis by increasing proliferation invasion, promotes malignancy tumor cells. Moreover, loss signaling can result therapy resistance Activation impairs metabolism via glycolysis inhibition. contrast PTEN, PI3K/Akt oncogenic during progression, enhances. shows positive association with pathways similar signaling, regulated non-coding RNAs. upregulation inhibition anti-cancer agents be beneficial interfering This review emphasizes networks related provides insights targeting this effective

Language: Английский

Citations

75
Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents DOI Open Access
Mehrdad Hashemi,

Motahare Sadat Ayat Mirdamadi,

Yasmin Talebi

et al.

Pharmacological Research, Journal Year: 2022, Volume and Issue: 187, P. 106568 - 106568

Published: Nov. 21, 2022

Language: Английский

Citations

72
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies DOI Open Access
Mehrdad Hashemi, Mohammad Arad Zandieh,

Yasmin Talebi

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 160, P. 114392 - 114392

Published: Feb. 15, 2023

Prostate cancer is among most malignant tumors around the world and this urological tumor can be developed as result of genomic mutations their accumulation during progression towards advanced stage. Due to lack specific symptoms in early stages prostate cancer, patients are diagnosed that cells display low response chemotherapy. Furthermore, enhance aggressiveness cells. Docetaxel paclitaxel suggested well-known compounds for chemotherapy they possess a similar function therapy based on inhibiting depolymerization microtubules, impairing balance microtubules subsequent delay cell cycle progression. The aim current review highlight mechanisms docetaxel resistance cancer. When oncogenic factors such CD133 upregulation PTEN tumor-suppressor shows decrease expression, malignancy enhances induce drug resistance. phytochemicals anti-tumor have been utilized suppressing chemoresistance Naringenin lovastatin used enhancing sensitivity. Moreover, nanostructures polymeric micelles nanobubbles delivery decreasing risk development. These subjects highlighted provide new insight reversing

Language: Английский

Citations

60
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance DOI

Zhenli Guo,

Milad Ashrafizadeh, Wei Zhang

et al.

Cancer and Metastasis Reviews, Journal Year: 2023, Volume and Issue: 43(1), P. 29 - 53

Published: July 15, 2023

Language: Английский

Citations

46
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation DOI
Milad Ashrafizadeh, Wei Zhang, Yu Tian

et al.

Cancer and Metastasis Reviews, Journal Year: 2024, Volume and Issue: 43(1), P. 229 - 260

Published: Feb. 19, 2024

Language: Английский

Citations

17
LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions DOI Open Access
Maliheh Entezari, Afshin Taheriazam,

Sima Orouei

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 154, P. 113609 - 113609

Published: Aug. 27, 2022

Epigenetic factors are critical regulators of biological and pathological mechanisms they could interact with different molecular pathways. Targeting epigenetic has been an idea approach in disease therapy, especially cancer. Accumulating evidence highlighted function long non-coding RNAs (lncRNAs) as cancer initiation development focused on their association downstream targets. microRNAs (miRNAs) the most well-known targets lncRNAs present review focuses lncRNA-miRNA axis malignancy therapy resistance tumors. LncRNA-miRNA regulates cell death such apoptosis autophagy cancers. This affects tumor metastasis via regulating EMT MMPs. Besides, determines sensitivity cells to chemotherapy, radiotherapy immunotherapy. Based studies, can be affected by drugs genetic tools this may affect expression level miRNAs targets, leading suppression/progression. LncRNAs have both tumor-promoting tumor-suppressor functions unique complicated implication therapy. also other signaling networks PI3K/Akt, STAT3, Wnt/β-catenin EZH2 among others. Notably, lncRNA/miRNA considered a signature for diagnosis prognosis

Language: Английский

Citations

55
FGFR families: biological functions and therapeutic interventions in tumors DOI Creative Commons
Qing Liu,

Jiyu Huang,

Weiwei Yan

et al.

MedComm, Journal Year: 2023, Volume and Issue: 4(5)

Published: Sept. 23, 2023

Abstract There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When FGFR binds to its ligand, (FGF), it dimerizes and autophosphorylates, thereby activating several key downstream pathways that play an important role in normal physiology, such as the Ras/Raf/mitogen‐activated protein kinase kinase/extracellular signal‐regulated kinase, phosphoinositide 3‐kinase (PI3K)/AKT, phospholipase C gamma/diacylglycerol/protein c, signal transducer activator of transcription pathways. Furthermore, oncogene, genetic alterations were found 7.1% tumors, these include gene amplification, mutations, fusions or rearrangements. Therefore, rearrangements, considered potential biomarkers therapeutic response for tyrosine inhibitors (TKIs). However, is worth noting with increased use, resistance TKIs inevitably develops, well‐known gatekeeper mutations. Thus, overcoming development drug becomes a serious problem. This review mainly outlines family functions, related pathways, agents tumors aim obtaining better outcomes cancer patients changes. The information provided this may provide additional ideas tumor abnormalities.

Language: Английский

Citations

39
Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation DOI
Yuan Gao, Man Tong, Tin Lok Wong

et al.

ACS Nano, Journal Year: 2023, Volume and Issue: 17(22), P. 22240 - 22258

Published: Nov. 15, 2023

Sorafenib, a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), has been shown to be potent ferroptosis inducer in HCC. However, we found that there was lower level of sorafenib-resistant HCC samples than sorafenib-sensitive samples, suggesting sorafenib resistance may result suppression. Recent reports have long noncoding RNAs (lncRNAs) are involved programmed cell death (PCD), including apoptosis and ferroptosis. This study aimed investigate the roles underlying molecular mechanisms lncRNAs sorafenib-induced cells. Using lncRNA sequencing, identified ferroptosis-related lncRNA, URB1-antisense RNA 1 (AS1), which highly expressed predicted poor survival Furthermore, URB1-AS1 mitigates by inducing ferritin phase separation reducing cellular free iron content. Hypoxia inducible factor (HIF)-1α as key promoting expression Notably, specifically inhibiting with N-acetylgalactosamine (GalNAc)-small interfering (si)URB1-AS1 successfully enhanced sensitivity cells an vivo tumor model. Our uncovered critical role repression ferroptosis, targeting represent potential approach overcome

Language: Английский

Citations

38
A comprehensive review on the emerging role of long non-coding RNAs in the regulation of NF-κB signaling in inflammatory lung diseases DOI
Asif Ahmad Bhat, Obaid Afzal, Neetu Agrawal

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 253, P. 126951 - 126951

Published: Sept. 19, 2023

Language: Английский

Citations

37